Editorial disclosure: This article is original educational commentary based on the cited literature. It summarizes and interprets published evidence rather than reproducing source text. Clinical decisions should be based on the full original publications, current guidelines, regulatory status, and individual patient factors.
Preserving location while adding molecular information
Kidney biopsy is a spatial diagnostic test: clinicians ask which cells are abnormal, where the lesion is located and how tissue architecture has changed. Spatial omics extends this principle by adding molecular information while retaining tissue location.
Spatial transcriptomics and related technologies can characterize gene expression in specific anatomical regions and cell populations. They complement single-cell and single-nucleus methods, which provide detailed molecular profiles but can lose spatial relationships during tissue dissociation.
Potential clinical value
Kidney diseases involve interactions among glomerular, tubular, vascular and immune compartments. Two biopsies may show similar conventional histology while having different molecular drivers. Digital pathology and deep-learning systems may quantify tissue features, support classification and integrate histology with molecular data.
These methods are not yet replacements for conventional pathology. They remain expensive and technically demanding, and clinical use requires standardization, adequate tissue, validated signatures and reliable analytical pipelines.
Key clinical takeaways
- Spatial omics preserves anatomical context while adding molecular information.
- Digital pathology and AI may augment conventional renal pathology.
- Clinical validation and standardization are still required.
References
- Yoshikawa T, et al. Next-generation kidney tissue analysis — spatial omics and digital pathology. Nat Rev Nephrol. 2026;22:603–621. DOI.